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Abstract
Purpose This study was undertaken to compare the
imaging findings of focal nodular hyperplasia (FNH) in
men and women, as seen on multidetector computed
tomography (MDCT), magnetic resonance imaging (MRI)
and contrast-enhanced ultrasound (CEUS).
Materials and methods Two radiologists reviewed 195
imaging studies (17 MDCT, 81 MRI and 97 CEUS
examinations) pertaining to 111 FNHs (mean size 3 cm) in
91 patients (mean age 39 years). For each lesion, the
readers assessed size, location, echogenicity, attenuation,
or signal intensity in comparison with adjacent liver
parenchyma on both unenhanced and postcontrast images.
Results Eighty-nine FNHs (mean size 3.1 cm) were
observed in 73 women (mean age 37.9 years) and 22 FNHs
(mean size 2.7 cm) in 18 men (mean age 41.2 years). No
statistically significant differences were found between
men and women in terms of age, FNH lesions per patient
(1.22 and 1.21, respectively), size, baseline and enhance-
ment pattern on MRI, CEUS and MDCT (p \ 0.05). A
central scar in FNHs was depicted in 4/18 (22.2 %) men
and 16/63 (25.4 %) women on MRI (p \ 0.05), and in 1/2
(50 %) men and 7/15 (46.7 %) women on MDCT
(p \ 0.05), whereas a spoke-wheel pattern, central scar,
and/or feeding vessel were seen in 5/17 (29.4 %) men and
22/80 (27.5 %) women on CEUS (p \ 0.05).
Conclusions Our results did not show any differences in
imaging features, age of occurrence and size of FNH
between men and women.
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Introduction
Hepatic focal nodular hyperplasia (FNH) is the second
most common liver tumour, the incidence of which is ris-
ing as a result of the widespread use of cross-sectional
imaging. FNH may occur in both sexes and at all ages, but
it is found most commonly in women (80–95 % of cases)
in their third to fourth decades of life, with a female-to-
male ratio of up to 5:1 [1].
Although the imaging findings of FNH are well
established, there is some controversy about the charac-
teristics of FNH with regard to patient gender [1, 2].
Luciani et al. [3] reported that in men the mean age at
diagnosis was significantly higher, the size was signifi-
cantly smaller and FNH showed more often atypical
imaging findings than those in women. Conversely,
Nguyen et al. [4] reported that the distribution of the
various morphological forms between women and men
was not significantly different. Furthermore, several
studies have demonstrated that detection of the typical
imaging features of FNH is often heavily dependent on
lesion size, being less frequent in lesions smaller than
3 cm [5–7]. We, therefore, undertook this study in an
attempt to clarify whether radiologists should expect any
gender differences in the imaging findings of FNH
detected in men or women.
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Materials and methods
Patient population and imaging techniques
Institutional review board approval was obtained and full
informed consent was waived for this retrospective study.
Our study complied with the terms of the Declaration of
Helsinki [8].
We searched our hospital’s medical records (radiology,
pathology, surgical pathology and discharge summary) to
identify patients with FNH treated during a 6-year period
(from January 2006 to December 2011). Patients were
eligible for enrolment on the basis of the following inclu-
sion criteria: (1) a conclusive diagnosis of FNH (see ref-
erence standard); (2) they had undergone at least one of the
following imaging studies: (a) baseline and contrast-
enhanced ultrasound (CEUS) scan; (b) multiphase multi-
detector computed tomography (MDCT) scan; (c) mag-
netic resonance imaging (MRI) with hepatocellular-specific
contrast agent. Patients were excluded from the analysis if
the imaging protocol was suboptimal or if the images could
not be retrieved from our imaging archives.
Computed tomography
CT studies were performed with a 64-slice MDCT scanner
(Brilliance 64, Philips Medical Systems, Eindhoven, The
Netherlands). Patients received 1.5 mL/kg total body
weight of 400 mgI/mL nonionic contrast agent (Iomeron
400, Bracco Imaging, Milan, Italy) infused with an auto-
mated injector (Medrad, Indianola, IA, USA) at a rate of
4 mL/s through a 18–20 gauge catheter inserted into an
antecubital vein. CT was performed immediately before
contrast agent administration and during the hepatic arte-
rial, hepatic venous and delayed phases. To determine the
scanning delay for the hepatic arterial phase, the time-to-
peak aortic enhancement was assessed using an automatic
bolus-tracking technique with automated scan-triggering
software (Bolus Pro Ultra, Philips Medical Systems,
Eindhoven, The Netherlands). Hepatic arterial phase
scanning was started automatically 18 s after the trigger
threshold (150 HU) reached the level of the suprarenal
abdominal aorta. The hepatic venous and delayed phases
were acquired 40 s after the beginning of the arterial phase
and 180 s after injection of contrast, respectively.
Magnetic resonance imaging
MRI was performed with a 1.5 T MR unit (Signa Excite
HDXT, General Electric Healthcare, Milwaukee, WI,
USA) using a phased-array multicoil. The MRI protocol
included precontrast axial breath-hold and respiratory-
triggered T2-weighted fast spin-echo (FSE) sequences both
with and without fat saturation (TR/TE 4,000/76 ms, flip
angle 150, section thickness 6 mm), unenhanced (in-phase
and out-of-phase) T1-weighted sequences (TR/TE
150/4.2–2.1 ms, flip angle 80, section thickness 4 mm)
and precontrast fat-saturated T1-weighted spoiled 3D gra-
dient-recalled echo (GRE) sequences (TR/TE 4.2/2.0 ms,
flip angle 12, section thickness 3 mm). A triphasic
dynamic contrast-enhanced study was obtained after the
administration of an IV bolus of 0.1 mmol/kg of gadobe-
nate dimeglumine (MultiHance, Bracco, Italy) into an
antecubital vein at a flow rate of 2 mL/s through a
20-gauge intravenous catheter by means of a power
injector (MR Spectris; Medrad, Pittsburgh, PA, USA) and
flushed by 20 mL of sterile saline solution. Images were
acquired using an automated bolus-detection technique
(Smartprep technique, GE Healthcare) during the arterial
(14 s after bolus injection), hepatic venous and delayed
phase (60 and 180 s after bolus injection, respectively).
The dynamic study was followed by a hepatocellular-spe-
cific phase obtained 2 h after the injection of contrast
material, with the same scanning parameters.
Contrast-enhanced ultrasound
Two experienced radiologists (more than 5 years of CEUS
of the liver), who were aware of the patients’ clinical
histories, performed US scanning using either an HDI 5000
(ATL, Bothell, Wash, USA) or an iU22 unit (Philips
Ultrasound, Bothell, Wash, USA), both of them equipped
with C5-2/C5-1 convex-array probes and pulse inversion
imaging software. A baseline survey, including colour/
power Doppler (CD/PD) and spectral analysis, was per-
formed. Once the US scan parameters had been set—such
as focal zone and time gain compensation—they were not
changed throughout the study. The US contrast agent used
in the present study was SonoVue (Bracco, Milan, Italy),
which was injected intravenously as a 2.4 mL bolus fol-
lowed by 10 mL of normal sterile saline flush using a 20-
or 22-gauge peripheral intravenous cannula. A low frame
rate (5 Hz) and a very low mechanical index (MI), ranging
from 0.05 to 0.08, were used for real-time imaging. One
focus was positioned below the level of the lesion. Each
examination lasted about 5 min after bolus injection. No
adverse events were recorded either during or immediately
after the injection of contrast agent. In patients with mul-
tiple lesions, a 2.4 mL further bolus of SonoVue was
administered for each lesion, with an interval time at least
of 15 min to allow for clearance of the previously injected
contrast.
Digital cineloops were recorded during both baseline
and postcontrast US in the arterial, hepatic venous and
extended hepatic venous or late phase (5–40 s, 55–90 s and
up to 200–300 s from the beginning of injection,
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respectively). All images and cineloops were digitally
stored as raw data in a PC-based workstation connected to
the US units via a standard Ethernet link and sent to our
PACS (Impax, Agfa-Gevaert, Milan, Italy).
Image analysis
Two abdominal radiologists (more than 10 years of expe-
rience) randomly reviewed all imaging studies by consen-
sus. Neither of the readers was involved in the scanning
and both were blinded to the final diagnosis, as well as to
the identity, clinical histories and other imaging findings of
the patients. Five consecutive interpretation sessions, with
a seven-day interval to prevent recall bias, were held to
complete the review process.
On each imaging modality, the two readers were asked
to report on the size and segment location of each lesion
according to the Couinaud classification system and to
visually assess echogenicity/attenuation/signal intensity
(the latter in all MRI sequences) in comparison with
adjacent liver parenchyma on both the unenhanced and the
contrast-enhanced images obtained during the arterial,
hepatic venous and delayed (or extended hepatic venous
for CEUS) phases. For MRI studies, the hepatocellular-
specific phase was also assessed. For US and CEUS stud-
ies, the colour Doppler images and spectral waveforms
were also evaluated for each lesion, as were the following
parameters [9–11]:
– ‘‘central scar’’: a central or eccentric hypo- or hyper-
echoic area at baseline US and/or unhenancing at
CEUS in the arterial and hepatic venous and extended
hepatic venous phase, also showing distinctly different
attenuation/intensity on unenhanced scans or at differ-
ent phases of enhancement.
– ‘‘feeding vessel’’: an arterial vessel, appreciable at
baseline CD/PD and/or at CEUS in the arterial phase,
branching from the hepatic arterial tree and directed
towards the lesion and penetrating it;
– ‘‘spoke-wheel’’ sign: a radial arterial vascularity within
the lesion appreciable at baseline colour and power
Doppler and/or centrifugal enhancement of the lesion
with a central vessel branching from the centre towards
the periphery at CEUS in the arterial phase.
– presence and type (arterial or venous) of any intrale-
sional flow, other than the above signs, at baseline
colour and power Doppler examination.
Reference standard
The final diagnosis was established by core biopsy per-
formed with an 18-G needle (n = 1) or by demonstrating
that FNH was iso- or hyperintense to the surrounding liver
in the hepatobiliary phase of MRI (n = 81). For the
remaining 29 lesions, a combination of size stability during
a follow-up period of at least 1 year and imaging features
consistent with FNH was used.
The CEUS diagnostic criteria for FNH were based on
arterial phase centrifugal filling and stellate vascularity,
followed by sustained contrast enhancement on the hepatic
venous phase and extended hepatic venous or late phase
[10]. The CT diagnostic criteria were: mild hypoattenua-
tion or isoattenuation on precontrast scan; rapid, homoge-
neous and strong enhancement in the arterial phase except
for the central scar; near isoattenuation to liver parenchyma
in the hepatic venous and delayed phases. The MRI diag-
nostic criteria were: iso- or slight hypointensity on T1-
weighted images; iso- or slight hyperintensity on T2-
weighted images; hyperintense central scar on T2-weighted
images; marked and homogeneous enhancement in the
arterial phase except for the central scar; iso- or slight
hyperintensity to liver parenchyma in the hepatic venous
and delayed phases [6, 7, 12].
Statistical analysis
Statistical analysis was performed by a biostatistician
involved in the study design, using a computer software
package (Intercooled Stata for Windows, v. 9.2., StateCorp,
TX, USA). To assess the statistical significance of the
difference between two genders with respect to US, colour
Doppler, CEUS, MDCT and MRI patterns and with respect
to the presence and appearance of the central scar, the z test
for proportions or the Fischer exact test were used, as
appropriate. Statistical significance was considered to be
present at a p value of \0.05.
Results
Overall, 195 complete imaging studies pertaining to 111
FNHs (size range 0.5–9.2 cm, mean 3 ± 1.8 cm) in 91
patients were retrieved (Table 1). There were 73 women
and 18 men (age range 18–77 years, mean 39 ± 14 years).
Table 1 Number and type of assessed imaging studies
No. of lesions MDCT MRI CEUS Total
Men 22 2 18 17 37
Women 89 15 63 80 158
Total 111 17 81 97 195
p value 0.365 0.297 0.111
MDCT multidetector computed tomography, MRI magnetic resonance
imaging, CEUS contrast-enhanced ultrasound
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Eighty-nine FNHs (size range 0.5–7.6 cm, mean
3.1 ± 1.7 cm) were observed in 73 women (age range
18–77 years, mean 37.9 ± 14.4 years) and 22 FNHs
(size range 0.7–9.2 cm, mean 2.7 ± 1.9 cm) in 18 men
(age range 25–76 years, mean 41.2 ± 16.9 years). Men
accounted for 19.8 % of all patients. No statistically
significant differences were found between the
two groups in terms of lesion size (p [ 0.05) or
mean number of FNH lesions per patient (1.22 vs. 1.21
FNH per patient in men and women, respectively)
(p [ 0.05).
Seventy-six patients (83.5 %) had one lesion, whereas in
the 15 patients who had more than one lesion (11 patients
with two lesions, three patients with three lesions and one
patient with four lesions), each lesion was studied sepa-
rately. Seventy-three (65.8 %) lesions were located in the
right liver and the remaining 38 (33.2 %) in the left liver.
Computed tomography
Eleven out of the 17 (64.7 %) FNHs studied by means of
MDCT were slightly hypoattenuating, whereas 4/17
Fig. 1 Focal nodular
hyperplasia (FNH) in a 48-year-
old man, multidetector
computed tomography
(MDCT). a Unenhanced scan
does not show any focal liver
lesion. b During the arterial
phase a markedly hypervascular
lesion (arrow) is evident in
segment VIII showing a tiny
hypoattenuating central area
corresponding to the central scar
(arrowhead). c, d The lesion
appears isoattenuating with
respect to the surrounding liver
parenchyma during the portal
venous and delayed phases
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(23.5 %) were isoattenuating and 2/17 (11.8 %) were
slightly hyperattenuating on the baseline unenhanced
images (p = 0.013).
After contrast agent injection, 17/17 (100 %) FNHs
became hyperattenuated to varying degrees in comparison
with adjacent liver parenchyma in the arterial phase and 13
of them (76.5 %) appeared isoattenuating both in the
hepatic venous and delayed phases, whereas 4/17 (23.5 %)
FNHs appeared hyperattenuating in the hepatic venous
phase. In the delayed phase, these four lesions were either
isoattenuating (n = 3) or hyperattenuating (n = 1).
A central scar was depicted on MDCT images as an
unenhancing hypoattenuating central area in 7/15 (46.7 %)
FNHs occuring in women and in one of the two (50 %)
FNHs in men. No statistically significant differences were
found between men and women (Fig. 1; Table 2).
Magnetic resonance imaging
Sixty-two out of 81 (76.5 %) FNHs studied with MRI were
slightly hypointense on baseline T1-weighted images and
72/81 (88.9 %) were slightly hyperintense on baseline T2-
weighted images (p = 0.038). No statistically significant
difference between men and women was found: 14/18
(77.8 %) vs. 48/63 (76.2 %) FNHs were hypointense on
T1-weighted images and 16/18 (88.9 %) vs. 56/63
(88.9 %) FNHs were hyperintense on T2-weighted images
in men and women, respectively (p [ 0.05). The remaining
four FNHs in men were isointense both on T1-weighted (4/
18; 22.2 %) and T2-weighted (2/18; 11.1 %) images,
whereas the remaining 15 FNHs in women were isointense
on T1-weighted images (15/63; 23.8 %), and showed iso-
intensity (6/63; 9.5 %) or hypointensity (1/63; 1.5 %) on
T2-weighted images, without any statistically significant
difference between men and women (p [ 0.05).
After contrast agent injection, 81/81 (100 %) FNHs
became hyperintense to varying degrees in comparison
with adjacent liver parenchyma in the arterial phase and 68
of them (83.9 %) appeared hyperintense in both the hepatic
venous and delayed phases (p = 0.0002), whereas 12/81
(14.8 %) FNHs showed isointensity in the hepatic venous
and delayed phases (Table 3; Fig. 2). One FNH showed
slight hypointensity in the hepatic venous phase but
appeared isointense in the delayed phase. All 81 FNHs
showed uptake of Gd-BOPTA in the hepatocellular-spe-
cific phase, appearing either hyperintense (70/81; 86.4 %)
or isointense (11/81; 13.6 %) (Fig. 2). No statistically
significant differences were found between men and
women (Table 3).
A central scar could be detected on MRI in 20/81
(24.7 %) FNHs, without any statistically significant dif-
ference between men (4/18; 22.2 %) and women (16/63;
25.4 %) (Fig. 2; Table 4). The central scar appeared more
frequently hypointense in men than in women in the
hepatic venous phase (p \ 0.006) (Table 4).
US, colour Doppler US and CEUS
Seventy-two out of the 97 (74.2 %) FNHs studied by
means of US were hypoechoic on baseline grey-scale US
images, but no statistically significant difference between
men and women was found (p [ 0.05).
At colour Doppler US at least one sign—spoke-wheel,
central scar, and/or feeding vessel sign—could be detected
in 37/97 (38.1 %) FNHs, without any statistically signifi-
cant difference between females and males (p [ 0.05).
Table 2 Multidetector CT pattern of 17 focal nodular hyperplasia (FNH) lesions
No. of lesions Unenhanced Arterial Hepatic venous Delayed Scar
Men 2/17 (11.8 %) 1 Iso
1 Hypo
2 Hyper 2 Hyper 1 Iso
1 Hyper
1 Hypo
Women 15/17 (88.2 %) 10 Hypo
3 Iso
2 Hyper
15 Hyper 13 Iso
2 Hyper
15 Iso 7 Hypo
p value 0.596 1.000 0.044 0.118 1.000
Table 3 Contrast-enhanced magnetic resonance imaging (MRI) patterns in 81 FNHs
Men Women Arterial Portal venous Delayed
16 (88.9 %) 52 (82.5 %) Hyperintense Hyperintense Hyperintense
2 (11.1 %) 10 (15.8 %) Hyperintense Isointense Isointense
– 1 (1.5 %) Hyperintense Hypointense Isointense
18 63 p value = 0.786
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After contrast agent injection, 95/97 (97.9 %) FNHs
showed hyperenhancement to varying degrees in compar-
ison with adjacent liver parenchyma in the arterial phase.
In the hepatic venous and late phases, all these 95 FNHs
were either isoenhancing (n = 67: 10 in men and 57 in
women) or slightly hyperenhancing (n = 28: seven in men
and 21 in women) in comparison with surrounding liver
parenchyma (Fig. 3). One FNH appeared isoenhancing
Fig. 2 FNH in a 31-year-old
man, magnetic resonance
imaging (MRI). a Unenhanced
MR shows a 3.5-cm isointense
(arrow) lesion in segment VI
which shows a small central
scar that is hypointense with
respect to the surrounding liver
parenchyma on T1-weighted
imaging (arrowhead). b The
lesion is slightly hyperintense
(arrow) but with a more
hyperintense central scar on the
T2-weighted image
(arrowhead). c In the arterial
phase the lesion shows marked
and homogeneous contrast
enhancement (arrow) except for
the hypointense central scar
(arrowhead). d The lesion
appears hyperintense during the
portal venous and delayed
phases (e) (arrows), whereas the
central scar appears constantly
hypointense (arrowheads).
f Two hours after the injection
of Gd-BOPTA the lesion shows
contrast uptake, appearing
slightly hyperintense in
comparison to the adjacent liver
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throughout the vascular phase and one FNH (sized 3.6 cm
and located in the subcapsular region of segment VII in a
‘‘bright’’ echogenic liver) remained hypoenhanced
throughout the vascular phase, but showed a spoke-wheel
sign in the arterial phase.
No statistically significant differences were noted
between females and males in contrast-enhancement pat-
tern at CEUS (p [ 0.05).
At least one sign—among spoke-wheel, central scar,
and/or feeding vessel—could be detected at CEUS in 27
out of 97 (27.8 %) FNHs. There was no statistically sig-
nificant difference between men and women: 5/17 (29.4 %)
signs in men and 22/80 (27.5 %) signs in women
(p [ 0.05).
Discussion
In the present study, FNHs occurring in men accounted for
19.8 % of all patients, confirming the higher prevalence in
females (4:1) and the previously reported trend of a higher
mean age at diagnosis in men (41 years) in comparison to
women (38 years), although this latter finding did not show
any statistically significant difference [1, 3]. Luciani et al.
[3] have also reported that FNHs arising in men are smaller
than those found in women (37.5 vs. 63.4 mm on average,
respectively) as well as a trend of fewer lesions per patient
in men (1.0 vs. 1.3 per patient). Although our series con-
firm the trend of a smaller size of FNHs in men (2.7 cm)
than in women (3.1 cm), no statistically significant
Table 4 MRI pattern of central scar detected in 20 FNHs
No. of scars T1-w T2-w Arterial Hepatic venous Delayed Hepato-specific
Men 4/18 (22.2 %) 2 Hypo 2 Hyper 4 Hypo 4 Hypo 1 Hypo
1 Hyper
1 Hypo
Women 16/63 (25.4 %) 9 Hypo 11 Hyper 16 Hypo 2 Hypo
8 Hyper
2 Hypo
7 Hyper
9 Hypo
p value (scar presence) 0.822 0.482 1.000 0.143 0.822 0.264
p value (scar appearance) 1.000 1.000 1.000 0.015 0.620 1.000
Fig. 3 FNH in a 27-year-old
man, contrast-enhanced
ultrasound (CEUS). a Baseline
US shows a 2.5-cm isoechoic
lesion located in the third
segment in subcapsular region
(arrow). b In the early arterial
phase, CEUS depicts the spoke-
wheel sign (arrow). c In the late
arterial phase, the lesion shows
clear-cut and homogeneous
contrast enhancement (arrow).
d The lesion appears slightly
hyperechoic to the surrounding
liver parenchyma in the
extended portal venous phase
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differences were found between the two groups in terms of
dimension, as well as in number of lesions per patient (1.22
vs. 1.21 FNH per patient in men and women, respectively)
(p [ 0.05). An explanation for these different results might
be related to the monocentric nature of both studies. Fur-
ther multicentric studies sampling a larger population may
be warranted to elucidate this issue.
In our series, no statistically significant differences
between men and women were found on unenhanced
images from US, MDCT and MRI.
After contrast agent injection, our findings confirm the
previously reported strong arterial enhancement on
dynamic contrast-enhanced images followed by sustained
enhancement, without any statistically significant differ-
ence among imaging modalities [5, 7, 10, 13]. In this
regard, although the study of Luciani et al. [3] mainly
focused on MRI findings, FNHs were reported to be less
often typical in men than in women (61.1 vs. 77.8 %), but
the described differences were not statistically significant
and no explanation for this finding was provided. Inter-
estingly, in that study the two men with FNH without
central stellate area on MR images had small lesions (25
and 30 mm in diameter, respectively), with no central
fibrous area on gross examination of the surgical specimen.
Several studies have demonstrated that the detection of
typical imaging features of FNH is often strongly, heavily
dependent on lesion size, being less frequent in lesions
smaller than 3 cm [5–7]. Consequently, considering our
series, it might be hypothesised that the difference found in
that study may be, at least in part, more closely related to
the different lesion size reported in the two different groups
of male and female patients than to real pathological dif-
ferences. Indeed, the abnormalities found at pathology in
men in that study were also described in women [4]. Fur-
thermore, the study by Luciani et al. did not use gadolinium
chelate with hepatocellular-specific properties, so the he-
patobiliary phase could not be exploited and, eventually,
the seven male patients with FNHs lacking at least one
typical finding on MRI underwent surgery. It is noteworthy
that all the FNHs studied in our series—whether in men or
women—showed uptake of hepatocellular-specific contrast
agent, demonstrating the hepatocellular nature of the
lesions and, in the proper clinical setting, their substantial
benignity. Hence, our data also support the hypothesis
made by other researchers that exploiting the properties of
the newer hepatocellular-specific MR contrast agents
enables us to depict the morphological and functional
characteristics of FNH noninvasively and may aid in the
differential diagnosis of these lesions, thus reducing the
need for biopsy and even surgery [13–15].
This retrospective study has some important limitations.
First, we had a selection bias. The patients were selected on
the basis of their presumed diagnosis in an imaging
database. Consequently, those with FNH lesions lacking
the characteristic imaging findings may have been missed.
Nevertheless, if atypical appearance of FNH is a feature
mainly observed in men we should have observed a dra-
matic reduction of typical FNHs found in men in com-
parison with women, but this was not the case. Second, the
final diagnosis was established in the majority of cases
without pathological evaluation because of ethical con-
cerns. However, all lesions were well characterised at
CEUS, multiphase contrast-enhanced CT and/or MRI on
the basis of the typical enhancement patterns, which we
considered to be established diagnostic criteria, as done in
other studies [14]. The third limitation was the lack of
multi-observer evaluation for imaging analysis.
Conclusions
Despite the above-mentioned limitations, our results do not
show any differences in the imaging features, age of
occurrence and size of FNH between men and women.
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